(Q64127566)

English

Mucosal priming with replicative Tiantan vaccinia and systemic boosting with DNA vaccine raised strong mucosal and systemic HIV-specific immune responses

article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18061316%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Mucosal priming with replicative Tiantan vaccinia and systemic boosting with DNA vaccine raised strong mucosal and systemic HIV-specific immune responses (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18061316%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18061316%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

author name string

Xianggang Huang

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18061316%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Lianxing Liu

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18061316%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Li Ren

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18061316%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Yanmin Wan

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18061316%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Jianqing Xu

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18061316%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

language of work or name

0 references

publication date

24 September 2007

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18061316%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18061316%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

25

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18061316%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

52

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18061316%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

8874-8884

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18061316%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Past, present and future of HIV vaccine trials in developing countries.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.066

7 January 2021

HIV vaccine strategies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.066

7 January 2021

HIV surveillance: a global perspective.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.066

7 January 2021

A consecutive priming-boosting vaccination of mice with simian immunodeficiency virus (SIV) gag/pol DNA and recombinant vaccinia virus strain DIs elicits effective anti-SIV immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.066

7 January 2021

HIV vaccines 1983-2003.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.066

7 January 2021

A human immunodeficiency virus 1 (HIV-1) clade A vaccine in clinical trials: stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.066

7 January 2021

HIV-specific mucosal and cellular immunity in HIV-seronegative partners of HIV-seropositive individuals

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.066

7 January 2021

Cytotoxic T cell responses to multiple conserved HIV epitopes in HIV-resistant prostitutes in Nairobi

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.066

7 January 2021

Induction of multifunctional human immunodeficiency virus type 1 (HIV-1)-specific T cells capable of proliferation in healthy subjects by using a prime-boost regimen of DNA- and modified vaccinia virus Ankara-vectored vaccines expressing HIV-1 Gag c

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.066

7 January 2021

Differential immunogenicity of various heterologous prime-boost vaccine regimens using DNA and viral vectors in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.066

7 January 2021

Characterization of Antibody Responses to Combinations of a Dengue Virus Type 2 DNA Vaccine and Two Dengue Virus Type 2 Protein Vaccines in Rhesus Macaques

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.066

7 January 2021

Immune responses in mice induced by prime-boost schemes of the Plasmodium falciparum apical membrane antigen 1 (PfAMA1)-based DNA, protein and recombinant modified vaccinia Ankara vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.066

7 January 2021

Avipox virus-vectored Japanese encephalitis virus vaccines: use as vaccine candidates in combination with purified subunit immunogens

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.066

7 January 2021

Anti-CD25 antibody enhancement of vaccine-induced immunogenicity: increased durable cellular immunity with reduced immunodominance

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.066

7 January 2021

DNA-based and alphavirus-vectored immunisation with prM and E proteins elicits long-lived and protective immunity against the flavivirus, Murray Valley encephalitis virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.066

7 January 2021

Protective immune responses induced by different recombinant vaccine regimes to Rift Valley fever.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.066

7 January 2021

Enhanced cellular immune responses to SIV Gag by immunization with influenza and vaccinia virus recombinants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.066

7 January 2021

Potent cellular and humoral immunity against HIV-1 elicited in mice by a DNA-prime/MVA-boost vaccine regimen intended for human use

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.066

7 January 2021

Synergistic DNA-MVA prime-boost vaccination regimes for malaria and tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.066

7 January 2021

Enhanced cellular immunity and systemic control of SHIV infection by combined parenteral and mucosal administration of a DNA prime MVA boost vaccine regimen.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.066

7 January 2021

Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.066

7 January 2021

Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.066

7 January 2021

Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.066

7 January 2021

Different patterns of immune responses but similar control of a simian-human immunodeficiency virus 89.6P mucosal challenge by modified vaccinia virus Ankara (MVA) and DNA/MVA vaccines.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.066

7 January 2021

The use of a systemic prime/mucosal boost strategy with an equine influenza ISCOM vaccine to induce protective immunity in horses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.066

7 January 2021

Prime-boost immunization with DNA vaccine: mucosal route of administration changes the rules

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.066

7 January 2021

Immunization of mice with recombinant gp41 in a systemic prime/mucosal boost protocol induces HIV-1-specific serum IgG and secretory IgA antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.066

7 January 2021

A call for replicating vector prime-protein boost strategies in HIV vaccine design

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.066

7 January 2021

Mucosal priming with PEI/DNA complex and systemic boosting with recombinant TianTan vaccinia stimulate vigorous mucosal and systemic immune responses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.066

7 January 2021

Cytokines as adjuvants for the induction of anti-human immunodeficiency virus peptide immunoglobulin G (IgG) and IgA antibodies in serum and mucosal secretions after nasal immunization

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.066

7 January 2021

Long-term immunity and protection against herpes simplex virus type 2 in the murine female genital tract after mucosal but not systemic immunization

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.066

7 January 2021

Intranasal immunization is superior to vaginal, gastric, or rectal immunization for the induction of systemic and mucosal anti-HIV antibody responses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.066

7 January 2021

Gender differences in human immunodeficiency virus type 1-specific CD8 responses in the reproductive tract and colon following nasal peptide priming and modified vaccinia virus Ankara boosting

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.066

7 January 2021

Vaccination strategies for mucosal immune responses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.066

7 January 2021

Recombinant poxviruses as mucosal vaccine vectors

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.066

7 January 2021

Adenoviral vectors for gene transfer and therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.066

7 January 2021

Heterologous protection against influenza by injection of DNA encoding a viral protein

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.066

7 January 2021

Prime-boost immunization generates a high frequency, high-avidity CD8(+) cytotoxic T lymphocyte population

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.066

7 January 2021

A T cell clone's avidity is a function of its activation state

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.066

7 January 2021

Selective expansion of high- or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.066

7 January 2021

Cytotoxic T lymphocytes directed against a tumor-specific mutated antigen display similar HLA tetramer binding but distinct functional avidity and tissue distribution.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.066

7 January 2021

Impact of vaccine-induced mucosal high-avidity CD8+ CTLs in delay of AIDS viral dissemination from mucosa

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.066

7 January 2021

Safety and immunogenicity of adenovirus-vectored nasal and epicutaneous influenza vaccines in humans.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.066

7 January 2021

Single mucosal, but not parenteral, immunization with recombinant adenoviral-based vaccine provides potent protection from pulmonary tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.066

7 January 2021

Adenovirus gene transfer causes inflammation in the brain

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.066

7 January 2021

Interleukin-1 mediates a rapid inflammatory response after injection of adenoviral vectors into the brain.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.066

7 January 2021

Phase I clinical trial safety of DNA- and modified virus Ankara-vectored human immunodeficiency virus type 1 (HIV-1) vaccines administered alone and in a prime-boost regime to healthy HIV-1-uninfected volunteers

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.066

7 January 2021

Safety profile of the viral vectors of attenuated fowlpox strain FP9 and modified vaccinia virus Ankara recombinant for either of 2 preerythrocytic malaria antigens, ME-TRAP or the circumsporozoite protein, in children and adults in Kenya

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.066

7 January 2021

The Future of Smallpox Vaccination: is MVA the key?

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.066

7 January 2021

A phase I vaccination study with tyrosinase in patients with stage II melanoma using recombinant modified vaccinia virus Ankara (MVA-hTyr).

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.066

7 January 2021

Identifiers

10.1016/J.VACCINE.2007.08.066

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18061316%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18061316%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q64127566&oldid=1368932312"